Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Breast and Ovarian Cancer Drug Extends Prostate Cancer Survival
Clinical Breakthroughs

Breast and Ovarian Cancer Drug Extends Prostate Cancer Survival

By Marla PaulSep 21, 2020
Share
Facebook Twitter Email

First genetically targeted treatment for metastatic prostate cancer that no longer responds to hormone therapy

Maha Hussain, MBChB, the Genevieve E. Teuton Professor of Medicine in the Division of Hematology and Oncology, a Northwestern Medicine oncologist, and co-leader of the PROfound trial, which investigated the drug olaparib.

Men with metastatic, hormone-resistant prostate cancer, who were treated based on the genetic makeup of their cancer, survived significantly longer than those treated with traditional hormone treatments, according to a large, international phase 3 clinical trial published in the New England Journal of Medicine and co-led by investigators from Northwestern Medicine, The Institute of Cancer Research in London and The Royal Marsden NHS Foundation Trust.

“Our results show genetically targeted treatment can extend the lives of patients with advanced prostate cancer that has progressed after several types of therapies, including hormone therapy,” said Maha Hussain, MBChB, the Genevieve E. Teuton Professor of Medicine in the Division of Hematology and Oncology, a Northwestern Medicine oncologist, and co-leader of the PROfound trial, which investigated the drug olaparib.

“We are now entering a new era of personalized care and precision medicine for metastatic prostate cancer. This will change clinical care for prostate cancer,” Hussain said.

Hussain is also deputy director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.


Listen to an episode of the Breakthroughs Podcast on this research:


Olaparib, currently used to treat breast, ovarian and pancreatic cancer, was used successfully to treat prostate cancers with an inability to repair damaged DNA.

“This marks a significant advance for prostate cancer treatment, which has lagged behind other common cancers with regard to precision therapy, now the standard of care in many cancers including breast, ovarian, pancreatic and lung cancers,” Hussain said.

The trial treated men with metastatic prostate cancer that had progressed after several types of prior standard therapies, including hormone therapy.

The trial preselected patients who have genetic alterations in the genes that enable cells to repair themselves from damage. Those most commonly known are the BRACA 1, BRACA 2 and ATM genes, but there are several others. Patients were randomly assigned to receive olaparib, which has been used in other cancers with similar genetic alterations, or standard hormone therapy with either abiraterone and prednisone or enzalutamide.

There were two cohorts of patients based on their cancer genetic mutations. The median duration of overall survival in patients in cohort A with mutations on BRCA1, BRCA2 or ATM genes was 19.1 months with olaparib compared to 14.7 months with control therapy, a number considered clinically and statistically significant.

In cohort B patients (those with other genetic mutations), the median overall survival was 14.1 months with olaparib and 11.5 months with control therapy, but this was not statistically significant.

In 2020, there will be an estimated 191,930 new cases of prostate cancer and about 33,330 deaths from it. Prostate cancer continues to be the second leading cause of cancer death in men in the United States. In 2016, there were an estimated 3,100,000 men living with prostate cancer in the U.S.

The trial had previously reported a delay in disease progression for this group of men with DNA repair faults in their tumors – but these final published results offer a longer follow-up and conclusively demonstrate an improvement in survival for men who were given olaparib.

Olaparib blocks PARP, a protein that helps damaged cells repair themselves. Some cancer cells rely on PARP to keep their DNA healthy. When PARP is stopped from repairing DNA damage, the cancer cells die.

“We want to prevent those renegade cancer cells from repairing themselves,” Hussain said.

The study was funded by AstraZeneca and Merck & Co., which produces olaparib under the name Lynparza.

Cancer Research Women in Medicine
Share. Facebook Twitter Email

Related Posts

Changes in Medical School Leadership

Jan 26, 2023

Shortage of Mental Health Professionals Linked to Increase in Youth Suicides

Jan 25, 2023

Understanding How Childhood Brain Tumors Develop

Jan 23, 2023

Comments are closed.

Latest News

Changes in Medical School Leadership

Jan 26, 2023

Shortage of Mental Health Professionals Linked to Increase in Youth Suicides

Jan 25, 2023

Northwestern Medicine Scholars Program Inspires a New Generation of Physicians and Scientists 

Jan 24, 2023

Understanding How Childhood Brain Tumors Develop

Jan 23, 2023

Medical School Establishes New Center for Psychiatric Neuroscience

Jan 19, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
Feinberg_In_Vivo_20221209_tcrawford-24
Feinberg_In_Vivo_20221209_tcrawford-16
Feinberg_In_Vivo_20221209_tcrawford-14
Feinberg_In_Vivo_20221209_tcrawford-5
Feinberg_In_Vivo_20221209_tcrawford-6
Feinberg_In_Vivo_20221209_tcrawford-10
Feinberg_In_Vivo_20221209_tcrawford-8
Feinberg_In_Vivo_20221209_tcrawford-18
Feinberg_In_Vivo_20221209_tcrawford
Feinberg_In_Vivo_20221209_tcrawford-23
Feinberg_In_Vivo_20221209_tcrawford-25
Feinberg_In_Vivo_20221209_tcrawford-26

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.